Zobrazeno 1 - 10
of 355
pro vyhledávání: ''
Publikováno v:
Journal of Clinical Oncology. 41:1331-1338
PURPOSE Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose
Autor:
Jitsuo Usuda, Susumu Takeuchi, Kengo Nagashima, Noriko Motoi, Masahiro Seike, Jun Matsubayashi, Hideaki Shiraishi, Kazufumi Honda, Shun-ichi Watanabe, Rintaro Noro, Kaoru Kubota, Xue Meng, Tatsuya Inoue, Huang Wilber, Ayumi Kashiro, Tetsuya Okano, Yukihiro Yoshida, Shinobu Kunugi, Akihiko Gemma, Norihiko Ikeda
Publikováno v:
Cancer Science. 113:1002-1009
Although adjuvant tegafur/uracil (UFT) is recommended for patients with completely resected stage I non-small cell lung cancer (NSCLC) in Japan, only one-third of cases has received adjuvant chemotherapy according to real-world data. Therefore, robus
Autor:
Atanas Ignatov, Piotr Czapiewski, Thomas Kalinski, Willi Pieper, Norbert Nass, Johannes Haybaeck
Publikováno v:
Cancer Biomarkers. 32:161-173
BACKGROUND: Neuronatin (NNAT) determined by immunohistochemistry is a negative prognostic biomarker for breast cancer, independent of the major clinicopathological markers. OBJECTIVE: Here, we investigated whether NNAT is also a predictive biomarker
Autor:
Zhao-Peng Zhang, Yan-bing Liu, Peng Chen, Xianrang Song, Tong Zhao, Li Xie, Chunjian Wang, Xingguo Song, Zhao Bi, Yong-Sheng Wang
Publikováno v:
Future Oncology. 17:2449-2460
The purpose was to integrate clinicopathological and laboratory indicators to predict axillary nodal pathologic complete response (apCR) after neoadjuvant therapy (NAT). The pretreatment clinicopathological and laboratory indicators of 416 clinical n
Publikováno v:
Future Oncology. 17:2183-2192
Aim: To investigate the benefit of chemotherapy among early-stage breast cancer patients with 21-gene recurrence scores of 26–30. Methods: We identified 3754 patients in the Surveillance, Epidemiology, and End Results database. Results: 57.6% of th
Autor:
Bianca Lederer, Arndt Hartmann, Hans Ulrich Ulmer, Wolfgang D. Schmitt, Sonia L. Villegas, Jutta Engel, Frank Holms, Andreas Schneeweiss, Bruno Valentin Sinn, Claus Hanusch, Michael Untch, Karsten Weber, Valentina Nekljudova, Marion van Mackelenbergh, Frederik Marmé, Hans Tesch, Clemens Heinrichs, Christian Albig, John Hackmann, Jens Huober, Christian Jackisch, Marion Kiechle, Nicole Pfarr, Wilko Weichert, Mahdi Rezai, Simone Schrodi, Carsten Denkert, Peter A. Fasching, Peter Sinn, Sibylle Loibl
Publikováno v:
European Journal of Cancer. 148:159-170
AIM To evaluate HER2-negative breast cancer (BC) with a low hormone receptor (HR) expression, with regard to pathological complete response (pCR) and survival, in comparison to triple-negative BC (TNBC) and strong HR-positive BC. METHODS We compared
Publikováno v:
Future Oncology. 17:1625-1635
Aim: PD-L1 is an important immune intervention target for lung cancer treatment; however, its clinical significance and biological function in circulating tumor cells (CTCs) of lung cancer need to be explored in depth. Materials & methods: In this st
Autor:
Yongliang Zhang, Heng Boon Low, Yik-Lam Cho, Herbert Schwarz, Nicholas R. J. Gascoigne, Fengchun Xiao, Chin Wen Png, Fiona Yi Xin Lee, Xiaohong Xu, Bangyuan Wu, Jia Min Loo, Han-Ming Shen, Li Ren Kong, Henry Yang, Ramanuj DasGupta, Zhen Lim Wong, Xuan Xin, Chun-Wei Li, Boon Cher Goh, Iain Beehuat Tan
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Nature Communications
Nature Communications
Drug resistance is a major obstacle to the treatment of most human tumors. In this study, we find that dual-specificity phosphatase 16 (DUSP16) regulates resistance to chemotherapy in nasopharyngeal carcinoma, colorectal cancer, gastric and breast ca
Autor:
Takafumi Soeno, Nobuyuki Nishizawa, Hiroki Harada, Keishi Yamashita, Hideki Ushiku, Keigo Yokoi, Naoki Hiki, Kei Hosoda
Publikováno v:
Journal of Surgical Research. 256:404-412
Background CDO1 is a presumed tumor suppressor gene in human cancers, the expression of which is silenced by promoter DNA methylation. Moreover, CDO1 harbors functionally oncogenic aspects through modification of mitochondrial membrane potential. We
Autor:
Nisha Ohri, Naomi Alpert, Mutlay Sayan, Jose A. Bazan, Ko Un Park, Emanuela Taioli, Daniel G. Stover, Sachin R. Jhawar, Julia White, Bruce G. Haffty, Mathew Cherian
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 22, Pp 8345-8354 (2020)
Cancer Medicine, Vol 9, Iss 22, Pp 8345-8354 (2020)
Background Breast conserving surgery (BCS) and adjuvant hormonal therapy (HT) without radiation therapy (RT) is an acceptable approach for older women with early stage, estrogen receptor (ER) positive breast cancer. Toxicity and compliance remain iss